TEACH: Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda

Sponsor
Yale University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05917210
Collaborator
National Institutes of Health (NIH) (NIH)
1,920
1
2
36
53.3

Study Details

Study Description

Brief Summary

This cluster-randomized trial in Uganda will evaluate the effectiveness and implementation of a novel, peer-led TB education and counseling strategy to improve outcomes among persons with tuberculosis (TB) with and without HIV/AIDS and assess the social-behavioral mechanisms underlying the observed treatment effects.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Standard TB-EC
  • Behavioral: Peer navigation strategy for TB-EC
N/A

Detailed Description

Study Design Aim 1. The investigators will conduct a parallel cluster-randomized hybrid Type 2 effectiveness-implementation trial at 16 sites.

Aim 2. Within the Aim 1 study, the investigators will nest a longitudinal observational study in both arms of the cluster-randomized trial to determine the feasibility, acceptability, and appropriateness of a peer-navigation strategy for TB-EC. The investigators will concurrently assess biological adherence using urine biomarkers) and will also perform a mediation analysis of social and behavioral factors (i.e., TB knowledge, perceived social support, general self-efficacy, HIV/TB stigma) to identify causal mechanisms of impact. Finally, the investigators will pilot and culturally adapt study instruments in a pilot study prior to the trial.

Aim 3. The investigators will also conduct a qualitative and mixed methods studies to assess the implementation fidelity and context of the peer-navigation strategy for TB-EC:

  1. Process evaluation of intervention fidelity to quantify the adoption, reach, implementation, and maintenance of the peer navigation strategy,

  2. In-depth interviews with people with Tuberculosis (PWTB) with and without HIV,

  3. In-depth interviews with and direct observation of peer navigators, and

  4. Focus-group discussions (FGDs) with healthcare workers.

The focus of this registration is Aim 1 and 2.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1920 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2026
Anticipated Study Completion Date :
Sep 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Peer navigation strategy for TB Education and Counseling (TB-EC)

peer-navigation strategy for TB-EC in adults and adolescents with and without HIV starting TB treatment at clinics in Uganda

Behavioral: Peer navigation strategy for TB-EC
multi-component, peer-navigation strategy for TB-EC

Active Comparator: Standard TB-EC

standard TB-EC in adults and adolescents with and without HIV starting TB treatment at clinics in Uganda

Behavioral: Standard TB-EC
Standard TB-EC by healthcare workers

Outcome Measures

Primary Outcome Measures

  1. Effectiveness assessed by TB treatment completion [up to 8 months post TB treatment initiation]

    The number of participants with TB treatment completion, defined by WHO as attending all refill visits and completing 180 daily doses of standard TB treatment within 8 months of TB treatment initiation, as documented in the on-site TB treatment register.

  2. Effectiveness assessed by Antiretroviral Therapy (ART) retention [month 12 post ART initiation]

    The number of participants with ART retention, defined as completing all ART refill visits (or refill pickups if enrolled in differentiated models of ART care) and continuing on daily ART 12 months after starting ART, as documented in the on-site ART register.

Secondary Outcome Measures

  1. Clinical Effectiveness assessed by TB recurrence-free survival [month 6 post TB-treatment]

    Clinical Effectiveness assessed by the number of participants with 6-month post-treatment TB recurrence-free survival. Data collectors at all sites will telephone participants and/or treatment supporters to document TB recurrence-free survival.

  2. Clinical Effectiveness assessed by HIV RNA copy number [month 12 post ART initiation]

    Clinical Effectiveness assessed by the number of participants with 12-month HIV RNA ≤50 copies/mL.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
TB outcomes:
  • Sites will enroll consecutive adults and older adolescents (age ≥18) recorded as new TB cases in the on-site National TB Program TB treatment register.
ART outcomes:
  • Participants must be documented as a People Living with HIV (PLH) in the TB register.
Exclusion Criteria:

TB outcomes: Individuals who are

  • transferring in from off-site

  • diagnosed with possible or confirmed drug-resistant TB

  • residing >40 km from the clinic

  • lacking mental capacity to participate in peer counseling

will be excluded from this study.

ART outcomes:
  • The investigators will exclude those with TB meningitis or TB pericarditis for which immediate ART is contraindicated; and those with central nervous system TB or TB osteomyelitis because these forms of TB have a different treatment duration.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Primary Care Clinics Kampala Uganda

Sponsors and Collaborators

  • Yale University
  • National Institutes of Health (NIH)

Investigators

  • Principal Investigator: J. Lucian Davis, MD, Yale University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT05917210
Other Study ID Numbers:
  • 2000035416
First Posted:
Jun 23, 2023
Last Update Posted:
Jun 23, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 23, 2023